COVID-19: big pharma confident on supply chain integrity

6 March 2020

As the novel coronavirus continues to spread across countries, concern about the potential for disruption to the manufacture and distribution of pharmaceutical products has intensified.

These anxieties have been exacerbated by the fact that COVID-19 struck first, and worst, in China - impacting key manufacturing operations for the life sciences industry.

There followed reports from the US Food and Drug Administration that an unnamed manufacturer had notified it of a human drug shortage, although at this point no shortage has been identified for products which cannot be replaced by others.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical